Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose sharply in pre-market after the company announced U.S. Food and Drug Administration approval of NEREUS (tradipitant), an oral neurokinin-1 receptor antagonist, for the prevention of motion-induced vomiting in adults.
Vanda Pharmaceuticals shares jumped 17.5% to $8.26 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
Now Read This:
Photo via Shutterstock